1el Mahallawy HA, Attia I, Ali el Din NH, et al. A prospective study on fungal infection in children with cancer. J Med Microbiol, 2002,51(7) :601-605.
2Al Jasser AM, Elkhizzi NA. Distribution of Candida species among bloodstream isolates. Saudi Med J, 2004, 25 (5) :566-569.
3St Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites:results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol, 2001, 39(3) :949-953.
4Mullen CA, Abd El Baki H, Samir H, et al. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients.Support Care Cancer,2003,11 (5) :321-325.
5Milton DK, Alwis KU, Fisette L, et al. Enzyme-linked immunosorbent assay specific for (1→6) branched, (1→3) - beta- D- glucan detection in environmental samples. Appl Environ Microbiol, 2001, 67(12) :5420-5424.
6Bow E J, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer, 2002, 94 ( 12 ): 3230-3246.
7Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A metaanalysis of 16 randomized, controlled trials. Cancer, 2000,89(7):1611-1625.
8Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol, 2003, 21 (24) :4615-4626.
9Hamacher J, Spiliopoulos A, Kurt AM, et al. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J, 1999,13 (1): 180-186.
10Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy, 2004, 24 (2 Pt 2):4S-28S; quiz 29S-32S.
